Search details
1.
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Nature
; 588(7836): 157-163, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33239784
2.
Biology and therapeutic targeting of molecular mechanisms in MPNs.
Blood
; 141(16): 1922-1933, 2023 04 20.
Article
in English
| MEDLINE | ID: mdl-36534936
3.
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms.
Genome Res
; 31(8): 1381-1394, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34244229
4.
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.
Blood
; 140(11): 1291-1304, 2022 09 15.
Article
in English
| MEDLINE | ID: mdl-35763665
5.
Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.
J Cell Mol Med
; 28(5): e17896, 2023 Aug 07.
Article
in English
| MEDLINE | ID: mdl-37551061
6.
Mechanical checkpoint regulates monocyte differentiation in fibrotic niches.
Nat Mater
; 21(8): 939-950, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35817965
7.
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Cancer Sci
; 113(2): 597-608, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34808021
8.
Mutant calreticulin in myeloproliferative neoplasms.
Blood
; 134(25): 2242-2248, 2019 12 19.
Article
in English
| MEDLINE | ID: mdl-31562135
9.
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Blood
; 131(7): 782-786, 2018 02 15.
Article
in English
| MEDLINE | ID: mdl-29288169
10.
Myeloproliferative neoplasm stem cells.
Blood
; 129(12): 1607-1616, 2017 03 23.
Article
in English
| MEDLINE | ID: mdl-28159736
11.
Two to tango! IL-13 and TGF-ß drive myelofibrosis.
Blood
; 140(26): 2767-2768, 2022 12 29.
Article
in English
| MEDLINE | ID: mdl-36580345
12.
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Nature
; 489(7414): 155-9, 2012 Sep 06.
Article
in English
| MEDLINE | ID: mdl-22820254
13.
Both sides now: losses and gains of mutant CALR.
Blood
; 135(2): 82-83, 2020 01 09.
Article
in English
| MEDLINE | ID: mdl-31917838
14.
Marked hyperferritinemia does not predict for HLH in the adult population.
Blood
; 125(10): 1548-52, 2015 Mar 05.
Article
in English
| MEDLINE | ID: mdl-25573993
15.
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.
Blood
; 125(6): 1014-24, 2015 Feb 05.
Article
in English
| MEDLINE | ID: mdl-25468568
16.
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Blood
; 125(2): 327-35, 2015 Jan 08.
Article
in English
| MEDLINE | ID: mdl-25281607
17.
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Proc Natl Acad Sci U S A
; 111(42): 15190-5, 2014 Oct 21.
Article
in English
| MEDLINE | ID: mdl-25288776
18.
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.
Br J Haematol
; 172(3): 412-9, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26537747
19.
Hit the spleen, JAK!
Blood
; 124(19): 2898-900, 2014 Nov 06.
Article
in English
| MEDLINE | ID: mdl-25377558
20.
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Blood
; 121(18): 3692-702, 2013 May 02.
Article
in English
| MEDLINE | ID: mdl-23487027